Search Weight Loss Topics:




Jun 10

Explained: Testosterone deficiency & the safety of replacement therapy – The Indian Express

Testosterone Comments Off on Explained: Testosterone deficiency & the safety of replacement therapy – The Indian Express

Hypogonadism is a condition caused by the deficiency of the male sex hormone, testosterone, and a new study in Lancet Health Longevity looks at the short- to medium-term safety of testosterone treatment. Analysis of data from more than 3,400 patients with hypogonadism from 17 clinical trials found little evidence that testosterone treatment increases the risk of cardiovascular events such as arrhythmia, heart attack, and stroke, in the short to medium terms.

Testosterone replacement therapy is the standard treatment for hypogonadism, which can cause sexual dysfunction, weakening of bones and muscles, and reduced quality of life. Risk factors include ageing (as testosterone levels decline with age), obesity and diabetes. Contacted via email, Dr Channa Jayasena, Reader in Reproductive Endocrinology, Imperial College London and study author, said that worldwide, 2% of men aged over 40 are affected, and this is growing as the population gets older.

Despite being widely used, the cardiovascular safety of testosterone treatment had so far remained unclear due to inconsistent findings. Most previous clinical studies relied on aggregate data, rather than individual participant data and have not published details of individual adverse events.

Prescribing of testosterone for hypogonadism is increasing globally, but conflicting messages about its safety may have led to many patients not receiving the treatment. Ongoing studies should help to determine the longer-term safety of testosterone but, in the meantime, our results provide much-needed reassurance about its short-to-medium term safety. Our findings could have important implications for the treatment of men with hypogonadism worldwide, lead author Jemma Hudson from the University of Aberdeen said in the report.

Funded by the UK National Institute for Health Research Health Technology Assessment Programme, the study identified 35 eligible clinical trials published since 1992, of which 17 provided individual participant data. None of the studies were from India, Dr Jayasena said.

In the 17 trials, 1,750 participants received testosterone and 1,681 were given a placebo. The average length of testosterone treatment was 9.5 months. The rate of cardiovascular events was not significantly higher for participants receiving testosterone treatment (7.5%) compared to placebo (7.2%). Fewer deaths were reported during testosterone treatment (0.4%) than in the placebo group (0.8%]), but these numbers were too small to establish whether testosterone reduced mortality risk, according to the study authors.

The researchers found that testosterone significantly reduced serum total cholesterol, HDL, and triglycerides compared with placebo.

However, there were no significant differences in LDL, blood pressure, glycaemic parameters, diabetes incidence, and prostate adverse outcomes between the testosterone and placebo groups, according to the report.

The authors have acknowledged some limitations to their study. There was little available data evaluating the cardiovascular safety of testosterone treatment beyond 12 months, and the very small number of deaths recorded during testosterone trials hampered the authors ability to analyse why they occurred. However, the longer-term safety of testosterone treatment is currently being investigated in another clinical trial, Dr Jayasena said.

Visit link:
Explained: Testosterone deficiency & the safety of replacement therapy - The Indian Express

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker